Guided Therapeutics, Inc. (GTHP) Announces Large LuViva Order
- European stocks hit three-week low as Trump reality sets in
- Qualcomm (QCOM) Calls Apple's (AAPL) Claims 'Baseless'
- Unease over Trump sends dollar to one-and-half month low
- Kate Spade (KATE) Said to Attract Interest from Coach (COH) and Michael Kors (KORS) - Bloomberg
- Oil falls as signs of U.S. output rise overshadow OPEC-led cuts
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Guided Therapeutics, Inc. (OTC: GTHP), developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care, today announced it has received an order for seven additional LuViva® Advanced Cervical Scans and 4,000 disposable Cervical Guides for Indonesia.
The order follows a recent recommendation that LuViva be included as an alternative to the Pap test at the 22nd Annual Scientific Meeting of the Society of Obstetricians and Gynecologists of Indonesia. The order brings to 14 the number of LuVivas and almost 7,000 the number of disposable Cervical Guides sold to Indonesia.
“We believe that the recommendation to include LuViva as an alternative to the Pap test will have a very positive effect for the product in Indonesia, the fourth most populous market in the world,” said Gene Cartwright, CEO and President of Guided Therapeutics, Inc. “Cervical cancer is the second most common malignancy among women of Indonesia with an incidence rate of about 17 in 100,000. In Indonesia, 70% of cervical cancer cases diagnosed are in the advanced stage, there is a clear unmet need to increase screening to detect cervical disease before it develops into cancer.”
In Indonesia, more than 93 million women are at risk of developing cervical cancer. Less than 25% of women aged 30 to 50 are screened for cervical cancer in Indonesia with the primary method of visual inspection with acetic acid.
There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xtant Medical Holdings (XTNT) Announces Resignation of CEO Dan Goldberger
- Sunesis Pharmaceuticals (SNSS) Says SNS-062 IND Application with FDA is Now Active, Continues Progress with Vosaroxin MAA
- AMC Entertainment (AMC) to Acquire Nordic Cinema Group for $929M
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!